UA81110C2 - Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine - Google Patents

Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine Download PDF

Info

Publication number
UA81110C2
UA81110C2 UA20040807114A UA20040807114A UA81110C2 UA 81110 C2 UA81110 C2 UA 81110C2 UA 20040807114 A UA20040807114 A UA 20040807114A UA 20040807114 A UA20040807114 A UA 20040807114A UA 81110 C2 UA81110 C2 UA 81110C2
Authority
UA
Ukraine
Prior art keywords
migraine
topiramate
treatment
dose
day
Prior art date
Application number
UA20040807114A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of UA81110C2 publication Critical patent/UA81110C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UA20040807114A 2002-02-26 2003-02-25 Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine UA81110C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (1)

Publication Number Publication Date
UA81110C2 true UA81110C2 (en) 2007-12-10

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040807114A UA81110C2 (en) 2002-02-26 2003-02-25 Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine

Country Status (18)

Country Link
US (2) US20030225002A1 (cg-RX-API-DMAC7.html)
EP (1) EP1478400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005518439A (cg-RX-API-DMAC7.html)
KR (1) KR101008326B1 (cg-RX-API-DMAC7.html)
CN (1) CN100352506C (cg-RX-API-DMAC7.html)
AU (1) AU2003213242A1 (cg-RX-API-DMAC7.html)
BR (1) BR0307951A (cg-RX-API-DMAC7.html)
CA (1) CA2419989A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040846A2 (cg-RX-API-DMAC7.html)
IL (2) IL163720A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008259A (cg-RX-API-DMAC7.html)
NO (1) NO20043984L (cg-RX-API-DMAC7.html)
NZ (1) NZ534874A (cg-RX-API-DMAC7.html)
PL (1) PL372393A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126093A (cg-RX-API-DMAC7.html)
UA (1) UA81110C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003072138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407729B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
JP2007523176A (ja) * 2004-02-17 2007-08-16 セプラコア インコーポレーテッド シタロプラム、エスシタロプラム又はシタロプラム代謝物質を用いる片頭痛又は頭痛疾患の治療又は病気の予防法
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
EP2023894A4 (en) * 2006-04-25 2010-10-20 Applied Pharma Res FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
BRPI0918623A2 (pt) * 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2018067330A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
DK3955933T3 (da) * 2019-04-15 2024-02-12 Vistagen Therapeutics Inc Behandling af migræne

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
EP0957928A1 (fr) * 1997-03-03 1999-11-24 Laboratoires Remilea Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
CN1182845C (zh) * 1999-01-19 2005-01-05 奥索-麦克尼尔药品公司 用于治疗集束性头痛的抗惊厥剂衍生物
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug

Also Published As

Publication number Publication date
CN100352506C (zh) 2007-12-05
EP1478400A1 (en) 2004-11-24
CN1646168A (zh) 2005-07-27
RU2004126093A (ru) 2005-04-10
IL163720A (en) 2012-06-28
JP2005518439A (ja) 2005-06-23
US20030225002A1 (en) 2003-12-04
IL163720A0 (en) 2005-12-18
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
NZ534874A (en) 2007-03-30
MXPA04008259A (es) 2005-05-27
AU2003213242A1 (en) 2003-09-09
KR20040091074A (ko) 2004-10-27
ZA200407729B (en) 2006-06-28
BR0307951A (pt) 2004-12-21
WO2003072138A1 (en) 2003-09-04
HRP20040846A2 (en) 2005-06-30
KR101008326B1 (ko) 2011-01-13
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
CA2419989A1 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
CN100352506C (zh) 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途
DK2035029T3 (en) PEPTID RELATIONS FOR TREATMENT OF REFRACTOR STATUS EPILEPTICUS.
AU2018341091A1 (en) Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamins in the treatment of epilepsy
KR20260027357A (ko) 편두통의 치료에 사용하기 위한 라스미디탄 및 cgrp 길항제의 조합 요법
HK1209323A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2288345B1 (en) Psycho-pharmaceuticals
Goonawardena et al. Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat
Auer et al. Functional characterization of novel bumetanide derivatives for epilepsy treatment
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
Bigal et al. New developments in migraine prophylaxis
AU2022234226B2 (en) Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
US20180221380A1 (en) Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia
EP3096790B1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
Roth Narcolepsy: treatment issues
KR20250059489A (ko) 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
EP1261324B1 (en) Use of tramadol for the preparation of a medicament for the treatment of functional gastrointestinal disorders
HK1080731B (en) Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments
Wiercisiewski et al. Drugs for management of acute and chronic behavioral disorders
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法
WO2005049039A1 (en) Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders